GLP-1 receptor agonists (RAs) are a therapy that help complete a comprehensive cardiorenal risk prevention strategy by targeting metabolic stress, systemic and renal inflammation, vascular dysfunction, and oxidative stress
JR: Writingoriginal draft
they cannot establish incidence, causation, or safe use
But the Alzheimers research is a good reminder that we shouldnt let our hopes and biases get in the way of the evidence, since early findings dont always hold up in larger clinical trials, says Gerardo Sison, Pharm.D., a member of the SingleCare Medical Review Board
10.1186/s12916-016-0560-3 81
It also provides a rationale for why morphinergic processes would have been conserved even at very low concentrations: subtle regulation of excitability and mitochondrial output could offer disproportionately large survival benefits